The self-injectable formulation of the inflammatory bowel disease treatment ‘Kynteles’ can now be prescribed at general hospitals in Korea.

According to industry sources, the subcutaneous injection formulation of Takeda Pharmaceuticals Korea’s Kynteles (vedolizumab) has passed the drug committee (DC) reviews in tertiary hospitals such as Samsung Medical Center and Seoul Asan Medical Center and other general hospitals including Kyungpook National University Hospital, Yeungnam University Medical Center, and Inje University Haeundae Paik Hospital.

The company has been quickly expanding its prescription area after the drug was listed for reimbursement in December last year.